Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroimaging evidence for a dopamine-independent association between motor cortex microstructure and Parkinson's disease severity.

NPJ Parkinson's disease·2026
Same author

Lower synaptic density in mood circuitry underlies depression in Parkinson's disease.

Brain communications·2026
Same author

Tear Film Imager Findings Support a New Perspective on the Mechanisms of Tear Film Thinning in Healthy Subjects.

Investigative ophthalmology & visual science·2026
Same author

Local Pain Collectives: A Novel Strategy for Improving Pain Knowledge, Pain Care and Community Connectedness in Rural Settings.

The Australian journal of rural health·2026
Same author

Optimized reference region and the effect on test-retest reliability and sensitivity to differences between Parkinson's disease and control groups with [<sup>11</sup>C]UCB-J.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

High-resolution mapping of introduced buffel grass (Cenchrus ciliaris) in central Australia.

Environmental monitoring and assessment·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Lauren Young1, Declan King2, Ya Yin Chang3

  • 1University of Edinburgh, Edinburgh, Scotland, United Kingdom.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

Synaptic Vesicle Glycoprotein 2A (SV2A) levels in Alzheimer

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Positron Emission Tomography (PET) studies in Alzheimer's disease (AD) use Synaptic Vesicle Glycoprotein 2A (SV2A) as a radioligand target.
  • Decreased SV2A PET signals in AD patients suggest potential as a biomarker for synaptic loss.
  • Uncertainty exists whether decreased signals reflect synapse loss or altered SV2A levels within synapses.

Purpose of the Study:

  • To validate Synaptic Vesicle Glycoprotein 2A (SV2A) as an accurate marker for detecting synapse loss in Alzheimer's disease (AD).
  • To differentiate between synapse loss and altered SV2A protein levels in remaining synapses in AD.

Main Methods:

  • Array tomography was used for high-resolution imaging and quantification of synapse density and protein colocalization.
  • SV2A puncta density, localization, and intensity were compared with synaptophysin, a known presynaptic marker.
  • Human post-mortem brain tissue from end-stage AD and age-matched controls (inferior temporal gyrus, dorsolateral prefrontal cortex, entorhinal cortex, cerebellum) were analyzed.

Main Results:

  • Strong correlations were observed between SV2A puncta density and synaptophysin puncta density, validating SV2A as a reliable marker of synapse density.
  • Significant differences in synapse density and disease-associated changes were found across brain regions.
  • Preliminary analysis indicated no significant differences in SV2A intensity within synaptic puncta between AD and control groups.

Conclusions:

  • Changes in SV2A PET signal in Alzheimer's disease likely reflect synapse density reduction, not altered protein levels in remaining synapses.
  • SV2A serves as a reliable marker for synapse density in post-mortem human brain tissue.
  • Further integration with in vivo PET imaging and molecular analyses is planned to confirm SV2A PET's clinical utility for synapse density assessment.